skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

About Amanda

Connecticut, USA

+20 year(s) experience

Amanda Micklus_Pharma_Intelligence
As Principal Analyst for Datamonitor Healthcare, Amanda Micklus provides coverage of corporate strategy and deal-making trends. She writes strategy reports for Datamonitor Healthcare, alongside articles and other content for In Vivo and Strategic Transactions.

With a focus on research and analysis of corporate strategy and deal-making, Amanda provides analysis of market-moving events that influence business development at leading companies.

 

Her particular areas of expertise include big pharma licensing and immuno-oncology deal-making, R&D strategies and pharma diversification.

Before joining Informa in 2005, Amanda worked as a market research analyst at specialty pharmaceutical company Purdue Pharma and had a previous role as a medical librarian/information searcher.

She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library and Information Science from Long Island University.

Analyst Articles

Articles by Amanda

  • Datamonitor Healthcare

    Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

    As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.

    Topic Cell and gene therapy

  • Datamonitor Healthcare

    Gene Therapy: A Paradigm Shift in Medicine

    Gene Therapy: A Paradigm Shift in Medicine

    The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

    Topic Cell and gene therapy

  • Datamonitor Healthcare

    R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?

    R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?

    In the developing pharma landscape, it’s important to consider all variables to create a winning portfolio strategy.

  • Medtrack

    Unpartnered Products: 2015 Update

    Unpartnered Products: 2015 Update

    The pharmaceutical industry is ripe for the picking with a virtual smorgasbord of unpartnered product opportunities in our 2015 update. As smaller biotech and pharma companies continue to

    Topic Deal trends

Tweets from Amanda